Efficacy News and Research

RSS

ESHRE's EIM: Europe leads in Assisted Reproduction Technology

Europe leads the world in Assisted Reproduction Technology (ART) with most cycles initiated in the region, the 26th Annual Meeting of the European Society of Human Reproduction and Embryology heard today (Wednesday 30 June).

30 Jun 2010

New approach to lung cancer measurement holds promise for smokers

The pilot program for Lung Cancer Alliance's (LCA) website for patient donated scans is helping open the door to a potentially new method for evaluating lung cancer risk in smokers as well as non-smokers.

30 Jun 2010

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

A new, effective, non-surgical treatment for uterine fibroids can help women with this condition maintain their fertility, an American scientist told the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome today (Wednesday).

30 Jun 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

Calmspace fragrance product to fight claustrophobia

Claustrophobia can be a debilitating condition and while there are a variety of therapies and treatments that attempt to limit its effects, there has never been a truly convenient, discreet and portable option for those seeking immediate and impactful relief in the event of an ensuing claustrophobic attack. Now, Healthy Brands LLC is introducing calmspace™, which delivers a proprietary therapeutic formula of 100% natural fragrance extracts that may help manage the anxiety resulting from claustrophobic reactions.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Experts evlauate impact of Medicare Part D program on independent and chain pharmacies

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Medicare Part D) added prescription drug coverage to Medicare beginning in January 2006.

30 Jun 2010

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.

30 Jun 2010

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

29 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

29 Jun 2010

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.

29 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.

29 Jun 2010

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.

29 Jun 2010

Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication

Pluristem Therapeutics Inc. today announced that following its meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP), the company is advancing toward designing two Phase IIb clinical trials for its placenta-derived cell therapy product, PLX-PAD, for the treatment of Critical Limb Ischemia (CLI) and Moderate-severe Claudication.

29 Jun 2010

Aggressive pursuit of low blood pressure, cholesterol levels may not benefit patients with diabetes

A mathematical model suggests that aggressively pursuing low blood pressure and cholesterol levels may not benefit, and could even harm, some patients with diabetes, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

Efficacy News and Research

ESHRE's EIM: Europe leads in Assisted Reproduction Technology

New approach to lung cancer measurement holds promise for smokers

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

UPA: An effective non-invasive treatment for fibroids can help maintain fertility in women

European Congress of Nephrology unveils results of various clinical trials

Calmspace fragrance product to fight claustrophobia

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Experts evlauate impact of Medicare Part D program on independent and chain pharmacies

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Alimera submits Iluvien NDA for DME to FDA

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

BIND Biosciences announces $12.4 million Series C-1 financing

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication

Aggressive pursuit of low blood pressure, cholesterol levels may not benefit patients with diabetes

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News